$2.31 Billion is the total value of Avoro Capital Advisors LLC's 32 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AMRN | Buy | AMARIN CORP PLCsponsored adr | $166,080,000 | +118.9% | 8,000,000 | +43.5% | 7.18% | +58.3% |
IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $100,148,000 | +10.3% | 10,530,862 | +2.6% | 4.33% | -20.2% |
MYOK | New | MYOKARDIA INC | $51,990,000 | – | 1,000,000 | +100.0% | 2.25% | – |
GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $50,284,000 | +250.0% | 950,000 | +171.4% | 2.17% | +153.1% |
ARRY | New | ARRAY BIOPHARMA INC | $48,760,000 | – | 2,000,000 | +100.0% | 2.11% | – |
MDCO | New | MEDICINES CO | $43,658,000 | – | 1,562,000 | +100.0% | 1.89% | – |
BDSI | Buy | BIODELIVERY SCIENCES INTL | $39,352,000 | +125.1% | 7,424,867 | +57.1% | 1.70% | +62.9% |
MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $38,831,000 | +53.1% | 310,000 | +37.8% | 1.68% | +10.8% |
ACAD | New | ACADIA PHARMACEUTICALS INC | $35,576,000 | – | 1,325,000 | +100.0% | 1.54% | – |
ALLO | Buy | ALLOGENE THERAPEUTICS INC | $29,793,000 | +7.4% | 1,128,594 | +0.0% | 1.29% | -22.4% |
CBAY | New | CYMABAY THERAPEUTICS INC | $9,628,000 | – | 725,000 | +100.0% | 0.42% | – |
XBI | New | SPDR SERIES TRUST - S&P BIOTECHput | $1,270,000 | – | 1,000,000 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.